Literature DB >> 12960182

99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.

Zeynep Burak1, Jean-Luc Moretti, Ozden Ersoy, Ulus Sanli, Mehmet Kantar, Feyzi Tamgac, Gülçin Basdemir.   

Abstract

UNLABELLED: In vitro studies have demonstrated that (99m)Tc-methoxyisobutylisonitrile ((99m)Tc-MIBI) is a transport substrate of multidrug resistance (MDR)-related proteins. The aim of this clinical study was to evaluate whether (99m)Tc-MIBI scintigraphy was a functional imaging tool for in vivo detection of multidrug resistance-associated protein (MRP) expression in osteosarcoma and to investigate the role of MRP and (99m)Tc-MIBI imaging to predict the clinical outcome. We also examined whether the scintigraphic parameters would help to distinguish the functional capacity of P-glycoprotein (Pgp) and MRP.
METHODS: Twenty-four patients with a diagnosis of osteosarcoma were studied before neoadjuvant chemotherapy. Tumor-to-background ratios of both early (10 min) and delayed (1 h) images and the percentage washout rate (WR%) of (99m)Tc-MIBI were calculated. Immunohistochemical analysis of MRP and Pgp was performed on biopsy specimens, and the response to preoperative chemotherapy was assessed by histopathologic examination.
RESULTS: Fifteen of 24 osteosarcoma samples in our series (62.5%) showed significant expression of MRP. The level of MRP expression was significantly correlated with the WR% of (99m)Tc-MIBI (r = 0.58, P = 0.003), and the WR% of (99m)Tc-MIBI was significantly faster in patients with high MRP expression than in those with a low MRP score (P = 0.007). The clearance rate of (99m)Tc-MIBI was significantly slower in tumor samples with negative or low expression of both Pgp and MRP (16% +/- 6.2%) when compared with osteosarcomas with high expression of both proteins (31.7% +/- 8.7%) (P = 0.001). There was not a significant difference between the WR% of (99m)Tc-MIBI in tumors with coexpression of both proteins and in tumors with high expression of either Pgp or MRP. Both the rate of MRP expression and the WR% of (99m)Tc-MIBI were significantly correlated with response rate.
CONCLUSION: Our results suggest that the WR% of (99m)Tc-MIBI is correlated with MRP expression. Both the WR% of (99m)Tc-MIBI and MRP expression are correlated with therapy response. (99m)Tc-MIBI can be used as a general probe for functional imaging of both Pgp and MRP; however, it is not capable of differentiating the functional status of either MDR-related glycoprotein.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960182

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

Review 1.  Pathology of primary malignant bone and cartilage tumours.

Authors:  L B Rozeman; A M Cleton-Jansen; P C W Hogendoorn
Journal:  Int Orthop       Date:  2006-08-30       Impact factor: 3.075

2.  To use MIBI or not to use MIBI? That is the question when assessing tumour cells.

Authors:  Jean-Luc Moretti; Nathalie Hauet; Meltem Caglar; Olivier Rebillard; Zeynep Burak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

3.  Pulmonary elimination rate of inhaled 99mTc-sestamibi radioaerosol is delayed in healthy cigarette smokers.

Authors:  Prina Ruparelia; Heok K Cheow; John W Evans; Leith Banney; Sonal Shankar; Katherine R Szczepura; Anna E Swift; James R Ballinger; Neil G Hartman; Edwin R Chilvers; A Michael Peters
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

4.  Predicting early chemotherapy response with technetium-99m methoxyisobutylisonitrile SPECT/CT in advanced non-small cell lung cancer.

Authors:  Tzu-I J Yang; Tjeerd S Aukema; Harm van Tinteren; Sjaak Burgers; Renato Valdés Olmos; Marcel Verheij
Journal:  Mol Imaging Biol       Date:  2009-09-12       Impact factor: 3.488

5.  Effects of neoadjuvant chemotherapy on image-directed planning of surgical resection for distal femoral osteosarcoma.

Authors:  Kevin B Jones; Peter C Ferguson; Brian Lam; David J Biau; Sevan Hopyan; Benjamin Deheshi; Anthony M Griffin; Lawrence M White; Jay S Wunder
Journal:  J Bone Joint Surg Am       Date:  2012-08-01       Impact factor: 5.284

6.  Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using 99mTc-sestamibi.

Authors:  Célia M F Gomes; Mick Welling; Ivo Que; Niek V Henriquez; Gabri van der Pluijm; Salvatore Romeo; Antero J Abrunhosa; M Filomena Botelho; Pancras C W Hogendoorn; Ernest K J Pauwels; Anne Marie Cleton-Jansen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-01       Impact factor: 9.236

7.  Influence of multidrug resistance on (18)F-FCH cellular uptake in a glioblastoma model.

Authors:  Claire Vanpouille; Nathalie Le Jeune; David Kryza; Anthony Clotagatide; Marc Janier; Francis Dubois; Nathalie Perek
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-20       Impact factor: 9.236

8.  Pituitary incidentalomas detected with technetium-99m MIBI in patients with suspected parathyroid adenoma: preliminary results.

Authors:  Ekaterina Tiktinsky; Tifha Horne; Michael Friger; Svetlana Agranovich; Sophie Lantsberg
Journal:  World J Nucl Med       Date:  2012-01

Review 9.  Predicting tumour response.

Authors:  Samuel D Kyle; W Phillip Law; Kenneth A Miles
Journal:  Cancer Imaging       Date:  2013-09-23       Impact factor: 3.909

10.  Cisplatin-resistant osteosarcoma cells possess cancer stem cell properties in a mouse model.

Authors:  Jian Yang; Weichun Guo; Lu Wang; Ling Yu; Hongjun Mei; Shuo Fang; Peng Ji; Yang Liu; Gaiwei Liu; Qi Song
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.